Subchronic administration of haloperidol influences the functional deficits of postnatal iron administration in Mice

Neurotoxicity Research

Volumn 10, Issue 2, 2006, Pages 123-129

  Fredriksson, Anders ^a   Archer, Trevor ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Basal ganglia; C57 BL6 Mice; DA D2 Receptor supersensitivity; Fe2+; Haloperidol; Iron administration; Locomotion; Movement disorder; Postnatal; Rearing; Schizopsychotic; Total activity; Vehicle

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; IRON;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BODY WEIGHT; C57BL MOUSE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INTERACTION; EXPLORATORY BEHAVIOR; FEMALE; MALE; MOTOR ACTIVITY; MOUSE; NEWBORN; PREGNANCY; STATISTICS; TIME;

ANIMALS; ANIMALS, NEWBORN; APOMORPHINE; BEHAVIOR, ANIMAL; BODY WEIGHT; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; FEMALE; HALOPERIDOL; IRON; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PREGNANCY; STATISTICS; TIME FACTORS;

EID: 34548756559     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033241     Document Type: Article

References (28)

1. Archer T, A Fredriksson, G Jonsson, T Lewander, AK Mohammed, SB Ross and U Soderberg (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology 88, 141-146.
2. Archer T, N Schröder and A Fredriksson (2003) Neurobehavioural deficits following postnatal iron overload: II Instrumental learning performance. Neurotoxicity Res. 5, 77-94.
3. 2 receptor supersensitivity. J. Neurochem. 54, 1136-1141.
4. Ben-Shachar D, and MB Youdim (1991) Intranigral iron injection induces behavioural and biochemical "parkinsonism" in rats. J. Neurochem. 57, 2133-2135.
5. 2 receptor supersensitivity by chronic iron salt treatment. Eur. J. Pharmacol. 202, 177-183.
6. Ben-Shachar D, E Livne, I Spanier, R Zuk and MB Youdim (1993) Iron modulates neuroleptic-induced effects related to the dopaminergic system. Isr. J. Med. Sci. 29, 587-592.
7. Boye SM and PP Rompre (2000) Behavioural evidence of depolarization blockade of dopamine neurons after chronic treatment with haloperidol and clozapine. J. Neurosci. 20, 1229-1239.
8. Dexter DT, FR Wells, F Agid, Y Agid, AJ Lees, P Jenner and CD Marsden (1987) Increased nigral iron content in postmortem parkinsonian brain [letter]. Lancet 2, 1219-1220.
9. Dexter DT, A Carayon, F Javoy-Agid, Y Agid, FR Wells, SE Daniel, AJ Lees, P Jenner and CD Marsden (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
10. Fredriksson A and T Archer (2003) Effect of postnatal iron administration on MPTP-induced behavioural deficits and neurotoxicity: behavioural enhancement by L-Dopa. Behav. Brain Res. 139, 31-46.
11. Fredriksson A and T Archer (2004) Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD. Neurotoxicity Res. 6, 435-456.
12. Fredriksson A, N Schroder, P Eriksson, I Izquierdo and T Archer (1999) Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol. Appl. Pharmacol. 159, 25-30.
13. Fredriksson A, N Schroder, P Eriksson, I Izquierdo and T Archer (2000) Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period. Brain Res. Dev. Brain Res. 119, 65-74.
14. Fredriksson A, N Schroder, P Eriksson, I Izquierdo and T Archer (2001) Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism & Rltd. Disord. 7, 97-105.
15. Fredriksson A, N Schroder and T Archer (2003) Neurobehavioural deficits following postnatal iron overload: I Spontaneous motor activity. Neurotoxicity Res. 5, 53-76.
16. Fredriksson A, P Eriksson and T Archer (2006) Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice. J. Neural Transm. 113, 137-150.
17. Gerlach M, D Ben-Shachar, P Riederer and MB Youdim (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807.
18. 3H]dopa in various regions of the brain. J. Neurochem. 13, 655-669.
19. Janetzky B, H Reichmann, MBH Youdim and P Riederer (1997) Iron and Oxidative Damage in Neurodegenerative Diseases (Willey-Liss), pp 407-421.
20. Kirk R (1995) Experimental Design: Procedures for the Behavioural Sciences (Brooks/Cole:BElmont, CA).
21. Riederer P, E Sofic, WD Rausch, B Schmidt, GP Reynolds, K Jellinger and MB Youdim (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
22. Saldana M, M Bonastre, E Aquilar and C Marin (2006) Role of nigral NFκB p50 and p65 subunit expression in haloperidol-induced neurotoxicity and stereotyped behaviour in rats. Eur. Neuropsychopharmacol. 16(7), 491-497.
23. Schroder N, A Fredriksson, M Vianna, R Roesler, I Izquierdo and T Archer (2001) Memory deficits in adult rats following postnatal iron administration. Behav. Brain Res. 124, 77-85.
24. Yehuda S and MB Youdim (1989) Brain iron: A lesson from animal models. Am. J. Clin. Nutr. 50(3 Suppl.), 618-629.
25. Youdim MB (2001) Deficiency and excess of iron in brain function and dysfunction. Nutr. Rev. 59, S83-S85.
26. Youdim MB, D Ben-Shachar and P Riederer (1991a) Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur. Neurol. 31, 34-40.
27. Youdim MB, D Ben-Shachar and P Riederer (1991b) The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8, 1-12.
28. Youdim MB, E Grunblatt and S Mandel (1999) The pivotal role of iron inNF-κB activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. NYAcad. Sci. 890, 7-25.